Heidari Amirhossein, Ghane Yekta, Heidari Nazila, Hosseini Seyedayin, Goodarzi Azadeh
Faculty of Medicine, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Ther Adv Chronic Dis. 2024 May 31;15:20406223241257342. doi: 10.1177/20406223241257342. eCollection 2024.
Hidradenitis suppurativa (HS) is an inflammatory skin condition with an underlying inflammatory process. Due to the limited efficacy of available treatments, HS remains a therapeutic challenge. The safety and efficacy of tumor necrosis factor-α (TNF-α) inhibitors, adalimumab, infliximab, and etanercept, are well studied in this patient population, and in some cases, HS was unresponsive to them. In recent years, evidence has been growing regarding the application of other anti-TNFs, including certolizumab pegol (CPZ) and golimumab. We sought to evaluate the overall safety and efficacy of golimumab and CPZ in the management of HS. A comprehensive search was performed on the PubMed, Scopus, Web of Science, and Ovid Embase databases, as well as the Google Scholar search engine from initiation to 31 August 2023. A total of nine and four studies used CPZ and golimumab to treat HS, respectively. Individuals with concomitant inflammatory immune-mediated diseases, pregnant females, and patients who were refractory to previous treatments achieved a Hidradenitis Suppurativa Clinical Response following CPZ administration. Also, golimumab showed promise in treating recalcitrant HS after the failure of other treatments, such as adalimumab and anti-interleukin-1. CPZ and golimumab can be efficacious treatment options for moderate-to-severe HS, especially in patients who are unresponsive to other TNF inhibitors, such as adalimumab.
化脓性汗腺炎（HS）是一种伴有潜在炎症过程的炎症性皮肤病。由于现有治疗方法疗效有限，HS仍然是一个治疗难题。肿瘤坏死因子-α（TNF-α）抑制剂阿达木单抗、英夫利昔单抗和依那西普在该患者群体中的安全性和疗效已得到充分研究，在某些情况下，HS对这些药物无反应。近年来，关于其他抗TNF药物（包括赛妥珠单抗聚乙二醇化修饰物（CPZ）和戈利木单抗）应用的证据越来越多。我们试图评估戈利木单抗和CPZ在HS治疗中的总体安全性和疗效。对PubMed、Scopus、Web of Science和Ovid Embase数据库以及谷歌学术搜索引擎进行了全面检索，检索时间从开始到2023年8月31日。分别有9项和4项研究使用CPZ和戈利木单抗治疗HS。患有合并炎症性免疫介导疾病的个体、怀孕女性以及对先前治疗难治的患者在使用CPZ治疗后实现了化脓性汗腺炎临床缓解。此外，在阿达木单抗和抗白细胞介素-1等其他治疗失败后，戈利木单抗在治疗顽固性HS方面显示出前景。CPZ和戈利木单抗可以成为中重度HS的有效治疗选择，尤其是对阿达木单抗等其他TNF抑制剂无反应的患者。
